To investigate urine ESM-1(endothelial cell specific molecule-1) as well as plasma ESM-1 level from renal allograft recipients, we show whether there is the difference of ESM-1 level according to allograft status.

We measured plasma and urine ESM-1 in 116 patients with underwent KTP. The concentration of ESM-1 was analyzed by enzyme linked immunosorbent assay (ELISA). According to allograft status, Groups are divided as stable, cellular rejection (CR), acute antibody-mediated rejection (AMR), long term good survival, and chronic AMR. We compared variables associated with graft status including plasma and urine ESM-1 between groups.

The distribution of plasma ESM-1 was not significantly different between all groups according to allograft status (p=0.131). On the other hand, the distribution of urine ESM-1 to creatinine ratio (urine ESM-1/Cr) was significantly different between all groups according to allograft status (p<0.001). In subgroup analysis, the distribution of urine ESM-1/Cr of stable group was significantly different from both CR and AMR groups. However, urine ESM-1/Cr of CR group was not significantly different from AMR group (p=0.063). Area under the curve (AUC) for differentiating AMR from CR was 0.774 (p<0.001).

Urine ESM-1 may reflect the possibility as biomarker of antibody-mediated rejection. Elevated urine ESM-1 level was associated with severity of glomerulitis, interstial fibrosis, glomerulopathy, arteriolar hyaline thickening, and peritubular capilaritis.

CITATION INFORMATION: Seo J.-W, Kim S.-Y, Kim Y.-G, Jeong Y.-H, Lee Y.-H, Moon J.-Y, Lee T.-W, Ihm C.-G, Lee S.-H. Detection of Endothelial Cell Specific Molecule-1 According to Allograft Status After Kidney Transplantation. Am J Transplant. 2016;16 (suppl 3).

« Back to 2016 American Transplant Congress